On June 26, Andros Pharmaceuticals announced on behalf of its subsidiary that the Phase I/IIa clinical trial for its novel drug APC201—designed to treat localized knee osteoarthritis pain—has yielded positive Phase II results in Australia. Both primary and secondary efficacy endpoints were met, indicating good overall safety and tolerability, with preliminary data showing a trend toward pain reduction in study participants.
These favorable results provide critical support for the design of Phase IIb/III trials. Clinical investigators have recommended proceeding with late-stage studies. Once the final trial report is completed, the company plans to outline a global multicenter Phase IIb/III clinical trial strategy and simultaneously initiate licensing discussions to accelerate commercialization.
The trial enrolled 60 patients using a randomized, placebo-controlled design. Participants applied either APC201 or a placebo to the knee area twice daily over a four-week period. The study included three groups: one applying APC201 in the morning and placebo at night, another using APC201 both morning and night, and a third using placebo both times. Safety and efficacy assessments were conducted at screening, Day 1, Day 8, and Day 29.
For the primary efficacy endpoint—pain score improvement—the group using APC201 both morning and night showed the greatest improvement (an increase of 1.73 points; p=0.1351), outperforming the placebo-only group. Notably, among participants reporting severe to extreme pain, APC201 demonstrated even greater pain reduction compared to placebo (an increase of 3.94 points; p=0.1005).
Secondary efficacy outcomes, including measures of joint stiffness, physical function, and patient self-assessment, also showed that APC201 helped reduce stiffness, improve mobility, and enhance overall treatment satisfaction.
On the safety front, APC201 was well tolerated and showed a lower incidence of skin irritation compared to the currently marketed topical product with the same active ingredient, Pennsaid 2% solution.
Andros noted that current treatments for osteoarthritis include oral medications, topical applications, intra-articular injections, and joint replacement surgery. Most patients prefer non-invasive topical options with minimal side effects. Among nonsteroidal anti-inflammatory drugs (NSAIDs), Pennsaid 2% holds the largest market share, with annual sales exceeding US$1 billion. However, its solvent DMSO is known to cause irritation and discomfort.
Developed in-house by Andros, APC201 uses a patented dual-action lipid formulation that increases the drug concentration to 4%, boosting its accumulation in the skin without using irritating solvents. This formulation minimizes skin-related side effects while enhancing therapeutic effectiveness. Once approved, APC201 is expected to offer patients a new treatment option and capture a share of the substantial osteoarthritis market.
According to Precedence Research, the global osteoarthritis treatment market is estimated at US$9.9 billion in 2024 and is projected to grow to US$24.3 billion by 2034, with a compound annual growth rate of 9.4%.
Resource: 竟天APC201新藥二期臨床正向 啟動全球授權
